X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (213) 213
humans (184) 184
male (178) 178
female (150) 150
cardiac & cardiovascular systems (143) 143
middle aged (123) 123
aged (101) 101
abridged index medicus (70) 70
adult (54) 54
animals (46) 46
aged, 80 and over (41) 41
echocardiography (40) 40
prospective studies (40) 40
mortality (39) 39
prognosis (39) 39
life sciences (37) 37
treatment outcome (37) 37
cardiovascular (35) 35
follow-up studies (31) 31
heart failure (31) 31
heart (30) 30
[ sdv.bbm ] life sciences [q-bio]/biochemistry, molecular biology (27) 27
cardiac patients (25) 25
cardiology (25) 25
electrocardiography (25) 25
pharmacology & pharmacy (23) 23
risk factors (23) 23
angioplasty (22) 22
heart attacks (22) 22
time factors (22) 22
biochemistry, molecular biology (20) 20
hemodynamics (20) 20
ischemia (20) 20
myocardial infarction (20) 20
stenosis (20) 20
care and treatment (19) 19
coronary angiography (19) 19
endothelium (19) 19
peripheral vascular disease (19) 19
analysis (18) 18
angioplasty, balloon, coronary (18) 18
severity of illness index (18) 18
disease (17) 17
dysfunction (17) 17
cardiovascular disease (16) 16
coronary disease - physiopathology (16) 16
echocardiography, doppler (16) 16
heart attack (16) 16
hemodynamics - drug effects (16) 16
mice (16) 16
predictive value of tests (16) 16
replacement (16) 16
ventricular function, left (16) 16
atherosclerosis (15) 15
cardiology and cardiovascular medicine (15) 15
coronary circulation - drug effects (15) 15
double-blind method (15) 15
high-risk patients (15) 15
outcomes (15) 15
reproducibility of results (15) 15
research (15) 15
risk assessment (15) 15
hypertension (14) 14
inflammation (14) 14
magnetic resonance imaging (14) 14
medical research (14) 14
percutaneous coronary intervention (14) 14
physiology (14) 14
radiology, nuclear medicine & medical imaging (14) 14
rats (14) 14
respiratory system (14) 14
stroke volume (14) 14
coronary circulation - physiology (13) 13
coronary disease - therapy (13) 13
coronary heart disease (13) 13
coronary vessels - drug effects (13) 13
endothelium, vascular - drug effects (13) 13
heart valve diseases (13) 13
heart-failure (13) 13
left-ventricular function (13) 13
myocardial infarction - physiopathology (13) 13
patients (13) 13
retrospective studies (13) 13
surgery (13) 13
cells, cultured (12) 12
conscious dogs (12) 12
dose-response relationship, drug (12) 12
heart failure - physiopathology (12) 12
hematology (12) 12
medical and health sciences (12) 12
medicin och hälsovetenskap (12) 12
mice, inbred c57bl (12) 12
pulmonary hypertension (12) 12
stents (12) 12
survival (12) 12
vasodilation - drug effects (12) 12
aortic valve stenosis - surgery (11) 11
blood flow velocity (11) 11
cardiac catheterization (11) 11
case-control studies (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 11, pp. 1011 - 1021
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2015, Volume 373, Issue 11, pp. 1021 - 1031
Patients with acute STEMI undergoing PCI were assigned to cyclosporine or placebo. No significant between-group difference was seen in the rate of death,... 
HEART | MEDICINE, GENERAL & INTERNAL | MITOCHONDRIAL PERMEABILITY TRANSITION | PERCUTANEOUS CORONARY INTERVENTION | INJECTION | REPERFUSION INJURY | SIZE | PORE | ISCHEMIA | CARDIOPROTECTION | ASPIRATION | Enzyme Inhibitors - adverse effects | Injections, Intravenous | Double-Blind Method | Humans | Middle Aged | Mortality | Kaplan-Meier Estimate | Male | Combined Modality Therapy | Enzyme Inhibitors - administration & dosage | Cyclophilins - antagonists & inhibitors | Myocardial Infarction - therapy | Myocardial Infarction - drug therapy | Cyclosporine - adverse effects | Cyclosporine - administration & dosage | Electrocardiography | Female | Aged | Heart Failure - epidemiology | Ventricular Remodeling - drug effects | Percutaneous Coronary Intervention | Care and treatment | Usage | Angiography | Heart enlargement | Dosage and administration | Cyclosporine | Heart attack | Occlusion | Myocardial infarction | Heart | Cerebral infarction | Heart attacks | Intravenous administration | Cyclosporins | Angioplasty | Body weight | Coronary artery | Clinical trials | Angina | Patients | Clinical outcomes | Reperfusion | Ventricle | Drug therapy | Heart diseases | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Bioengineering | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 04/2013, Volume 187, Issue 7, pp. 703 - 714
Journal Article
Journal Article
Cardiovascular research, ISSN 0008-6363, 01/2019
Increase of cardiac cAMP bioavailability and PKA activity through adenylyl-cyclase 8 (AC8) overexpression enhances contractile function in young transgenic... 
Journal Article
by White, Harvey D and Held, Claes and Stewart, Ralph and Tarka, Elizabeth and Brown, Rebekkah and Davies, Richard Y and Budaj, Anzej and Harrington, Robert A and Steg, P. Gabriel and Ardissino, Diego and Armstrong, Paul W and Avezum, Alvaro and Aylward, Philip E and Bryce, Alfonso and Chen, Hong and Chen, Ming-Fong and Corbalan, Ramon and Dalby, Anthony J and Danchin, Nicolas and de Winter, Robbert J and Denchev, Stefan and Diaz, Rafael and Elisaf, Moses and Flather, Marcus D and Goudev, Assen R and Granger, Christopher B and Grinfeld, Liliana and Hochman, Judith S and Husted, Steen and Kim, Hyo-Soo and Koenig, Wolfgang and Linhart, Ales and Lonn, Eva and López-Sendón, José and Manolis, Athanasios J and Mohler, Emile R and Nicolau, José C and Pais, Prem and Parkhomenko, Alexander and Pedersen, Terje R and Pella, Daniel and Ramos-Corrales, Marco A and Ruda, Mikhail and Sereg, Mátyás and Siddique, Saulat and Sinnaeve, Peter and Smith, Peter and Sritara, Piyamitr and Swart, Henk P and Sy, Rody G and Teramoto, Tamio and Tse, Hung-Fat and Watson, David and Weaver, W. Douglas and Weiss, Robert and Viigimaa, Margus and Vinereanu, gos and Zhu, Junren and Cannon, Christopher P and Wallentin, Lars and Steg, Ph Gabriel and Bucan, Olga and Elfström, Charlotta and Hegg, Lisa and Jarosz, Marie and Krug-Gourley, Sue and Rudman, Jerry and Collins, Rory and Anderson, Jeffrey and DeMets, David and Ganz, Peter and Sandercock, Peter and Weber, Michael and Fisher, Marian and Buhr, Kevin and Diegel, Scott and Schultz, Melissa and Mahaffey, Kenneth W and Alexander, John H and Al-Khatib, Sana and Baron, Tomasz and Bergström, Olle and Bushnell, Cheryl and Christersson, Christina and Eggers, Kai and Fredlund, Bengt-Olov and Hagström, Emil and Hijazi, Ziad and Örndahl, Lovisa Holm and James, Stefan K and Jernberg, Tomas and Johnston, Nina and Lopez, Renato D and Mehta, Rajena H and Newby, Kristin L and Nordmark, Örjan and Oldgren, Jonas and Roe, Matthew T and Saldéen, Katarina and Stenborg, Anna and ... and The STABILITY Investigators and STABILITY Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
TRIAL | LIPOPROTEIN | MEDICINE, GENERAL & INTERNAL | THERAPY | ACTIVATING-FACTOR ACETYLHYDROLASE | OXIDIZED LDL | RISK | PHOSPHOLIPASE A | ATHEROSCLEROTIC PLAQUE | INHIBITOR | CLINICAL-OUTCOMES | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Index Medicus | Abridged Index Medicus | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
European Heart Journal, ISSN 0195-668X, 01/2015, Volume 36, Issue 2, pp. 112 - 119
Journal Article